Dopa-responsive dystonia

Handbook of Dystonia

Volumn , Issue , 2006, Pages 219-244

  Segawa, Masaya ^a   Nomura, Yoshiko ^a   Nishiyama, Nobuyoshi ^b  

^a Segawa Neurological Clinic for Children   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057471053     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (140)

1. Nygaard TG, Marsden CD, Duvoisin RC. Dopa responsive dystonia. Adv Neurol 1988; 50: 377-384.
2. Calne DB. Dopa-responsive dystonia. Ann Neurol 1994; 35: 381-382.
3. Segawa M, Ohmi K, Itoh S, et al. Childhood basal ganglia disease with remarkable response to Levodopa, hereditary basal ganglia disease with marked diurnal fluctuation (Japanese). Shinryo (Tokyo) 1971; 24: 667-672.
4. Segawa M, Hosaka A, Miyagawa F, et al. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 1976; 14: 215-233.
5. Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation (HPD) (Japanese). Adv Neurol Sci (Tokyo) 1981; 25: 73-81.
6. Deonna T. Dopa-responsive progressive dystonia of childhood with fluctuations of symptoms-Segawa’s syndrome and possible variants. Neuropediatrics 1986; 17: 81-85.
7. Nomura Y, Segawa M. Intrafamilial and interfamilial variations of symptoms of Japanese hereditary progressive dystonia with marked diurnal fluctuation. In: Segawa M, ed. Hereditary Progressive Dystonia with Marked Diurnal Fluctuation. Carnforth: Parthenon, 1993: 73-96.
8. Bandmann O, Nygaard TG, Surtees R, et al. Dopa responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum Mol Genet 1996; 5: 403-406.
9. Bandmann O, Valene EM, Holmans P, et al. Dopa-responsive dystonia: a clinical and molecular genetic study. Ann Neurol 1998; 44: 649-656.
10. Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 2003; 54: 32-45.
11. Segawa M, Hoshino K, Hachimori K, et al. A single gene for dystonia involves both or either of the two striatal pathway. In: Bicholson L, Baull R, eds. The Basal Ganglia VI. New York: Kluwer Academic/Plenum Publishers, 2002: 155-163.
12. Furukawa Y, Kish SJ, Bebin EM, et al. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann Neurol 1998; 44: 10-16.
13. Leuzzi V, Carducci C, Carducci C, et al. Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome. Neurology 2002; 59: 1241-1243.
14. Segawa M, Nomura Y, Kase M. Diurnally fluctuating hereditary progressive dystonia. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Extrapyramidal Disorders. Vol. 5. Amsterdam: Elsevier, 491986: 529-539.
15. Segawa M, Nomura Y, Yamashita S, et al. Long-term effects of Levodopa on hereditary progressive dystonia with marked diurnal fluctuation. In: Berardelli A, Benecke R, Manfredi M, Marsden CD, eds. Motor Disturbance II. London, New York: Academic Press, 1990: 305-318.
16. Segawa M, Nomura Y. Hereditary progressive dystonia with marked diurnal fluctuation and dopa-responsive dystonia: Pathognomonic clinical features. In: Segawa M, Nomura Y, eds. Age-Related Dopamine-Dependent Disorders. Vol. 14. Basel: Karger, 1995: 10-24.
17. Segawa M, Nomura Y, Yukishita S, et al. Is phenotypic variation of hereditary progressive dystonia with marked diurnal fluctuation/dopa-responsive dystonia (HPD/DRD) caused by the difference of the locus of mutation on the GTP cyclohydrolase 1 (GCH-1) gene? Adv Neurol 2004; 94: 217-223.
18. Furukawa Y, Filiano JJ, Kish SJ. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. Mov Disord 2004; 19: 1256-1258.
19. Nomura K, Negoro T, Takesu E, et al. Bromocriptine therapy in a case of hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 1987; 9: 199.
20. Ibi T, Sahashi K, Watanabe K, et al. Progressive dystonia with marked diurnal fluctuation and tetrahydrobiopterin therapy (Japanese). Neurol Ther (Tokyo) 1991; 8: 71-75.
21. Ishida A, Takada G, Kobayashi Y, et al. Involvement of serotonergic neurons in hereditary progressive dystonia; Clinical effects of tetrahydrobiopterin and 5-hydroxytryptophan (Japanese). No-To-Hattatsu (Tokyo) 1988; 20: 196-199.
22. Le Witt PA, Miller LP, Newman RP, et al. Pterdine cofactor in dystonia: Pathogenic and therapeutic considerations. Neurology 1983; 33(Suppl 2): 161.
23. Le Witt PA, Miller LP, Newman RP, et al. Treatment of dystonia with tetrahydrobiopterin. N Engl J Med 1983; 308: 157-158.
24. Le Witt PA, Miller LP, Newman RP, et al. Tetrahydrobiopterin in dystonia: Identification of abnormal metabolism and therapeutic trials. Neurology 1986; 36: 760-764.
25. Segawa N, Nomura Y, Takita K, et al. Pallidotomy and thalamotomy on a case with hereditary progressive dystonia with marked diurnal fluctuation. Mov Disord 1998; 13(Suppl 2): S165.
26. Kumamoto I, Nomoto M, Yoshidome M, et al. Five cases of dystonia with marked diurnal fluctuation and special reference to homovanilic acid in CSF (Japanese). Clin Neurol (Tokyo) 1984; 24: 697-702.
27. Maekawa N, Hashimoto T, Sasaki M, et al. A study on catecholamine metabolites in CSF in a patient with progressive dystonia with marked diurnal fluctuation (Japanese). Clin Neurol (Tokyo) 1988; 28: 1206-1208.
28. Ouvrie RA. Progressive dystonia with marked diurnal fluctuation. Ann Neurol 1978; 4: 412-417.
29. Shimoyamada Y, Yoshikawa A, Kashii H, et al. Hereditary progressive dystonia-an observation of the catecholamine metabolism during Levodopa therapy in a nine-yearold girl (Japanese). No-To-Hattatsu (Tokyo) 1986; 18: 505-509.
30. Fink JK, Barton N, Cohen W, et al. Dystonia with marked diurnal variation associated with bioperin deficiency. Neurology 1988; 38: 707-711.
31. Fujita S, Shintaku H. Etiology and pteridine metabolism abnormality of hereditary progressive dystonia with marked diurnal fluctuation (HPD: Segawa disease). Med J Kushiro City Hosp 1990; 2: 64-67.
32. Furukawa Y, Nishi K, Kondo T, et al. CSF biopterin levels and clinical features of patients with juvenile parkinsonism. Adv Neurol 1993; 60: 562-567.
33. Takahashi H, Snow B, Nygaard T, et al. Fluorodopa PET scans of juvenile parkinsonism with prominent dystonia in relation to dopa-responsive dystonia. In: Segawa M, Nomura Y, eds. Age-Related Dopamine-Dependent Disorders. Basel: Karger, 1995: 86-94.
34. Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994; 8: 236-242.
35. Hyland K, Fryburg JS, Wilson WG. Oral phenylalanine loading in dopa responsive dystonia; a possible diagnostic test. Neurology 1997; 48: 1290-1297.
36. Snow BJ, Okada A, Martin WRW, et al. Positron-emission tomography scanning in dopa-responsive dystonia, parkinsonism-dystonia, and young onset parkinsonism. In: Segawa M, ed. Hereditary Progressive Dystonia with Marked Diurnal Fluctuation. Carnforth: Parthenon, 1993: 181-186.
37. Sawle GB, Lenders KL, Brooks DJ, et al. Dopa-responsive dystonia: (F-18) Dopa positron emission tomography. Ann Neurol 1991; 30: 24-30.
38. Turjanski N, Weeks R, Sawle GV, et al. Positron emission tomography studies of the dopaminergic and opioid function in dopa-responsive dystonia. In: Segawa M, Nomura YM, eds. Age-Related Dopamine-Dependent Disorders. Basel: Karger, 1995: 77-86.
39. Okada A, Nakamura K, Snow BJ, et al. PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa’s disease): case report. Adv Neurol 1993; 60: 591-594.
40. Takahashi H, Levine RA, Galloway MP, et al. Biochemical and fluorodopa positron emission tomographic findings in an asymptomatic carrier of the gene for doparesponsive dystonia. Ann Neurol 1994; 35: 354-356.
41. Leenders KL, Antonini A, Meinck, et al. Striatal dopamine D2 receptors in doparesponsive dystonia and Parkinson’s disease. In: Segawa M, Nomura Y, eds. Age-Related Dopamine-Dependent Disorders. Basel: Karger, 1995: 95-100.
42. Kishore A, Nygaard TG, de la Fuente-Fernandez R, et al. Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with (11C) raclopride and positron-emission tomography. Neurology 1998; 50: 1028-1032.
43. Kunig G, Leenders KL, Antonini A, et al. D2 receptor binding in dopa-responsive dystonia. Ann Neurol 1988; 44: 758-762.
44. Jeon BS, Jeong JM, Park SS, et al. Dopamine transporter density measured by (123I) b-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998; 43: 792-800.
45. Segawa M, Nomura Y, Hikosaka O, et al. Roles of the basal ganglia and related structures in symptoms of dystonia. In: Carpenter MB, Jayaraman A, eds. The Basal Ganglia VI. New York: Kluwer Academic/Plenum Publishers, 2002: 489-504.
46. Segawa M, Nomura Y, Tanaka S, et al. Hereditary progressive dystonia with marked diurnal fluctuation: Consideration on its pathophysiology based on the characteristics of clinical and polysomnographical findings. Adv Neurol 1988; 50: 367-376.
47. Segawa M, Nomura Y. Hereditary progressive dystonia with marked diurnal fluctuation. Pathophysiological importance of the age of onset. Adv Neurol 1993; 60: 568-576.
48. Segawa M, Nomura Y. Rapid eye movements during stage REM are modulated by nigrostriatal dopamine (NS-DA) neuron? In: Bernardi G, Carpenter MB, Di Chiara G, et al., eds The Basal Ganglia III. New York: Kluwer Academic/Plenum Publishers, 1991: 663-671.
49. Hikosaka O, Sakamoto M, Usui S. Functional properties of monkey caudate neurons. I. Activities related to saccadic eye movements. J Neurophysiol 1989; 61: 780-798.
50. Hikosaka O, Fukuda H, Kato M, et al. Deficits in saccadic eye movements in hereditary progressive dystonia with marked diurnal fluctuation. In: Segawa M, ed. Hereditary Progressive Dystonia with Marked Diurnal Fluctation. Carnforth: Parthenon, 1993: 159-177.
51. Muller K, Homberg V, Lenard HG. Motor control in child hood onset dopa-responsive dystonia (Segawa syndrome). Neuropediatrics 1989; 20: 185-191.
52. Rajput AH, Gibb WRG, Zhong XH, et al. Dopa-responsive dystonia: pathological and biochemical observations in one case. Ann Neurol 1994; 35: 396-402.
53. Hornykiewicz O. Striatal dopamine in dopa-responsive dystonia: Comparison with idiopathic Parkinson’s disease and other dopamine-dependent disorders. In: Segawa M, Nomura YM, eds. Age-Related Dopamine-Dependent Disorders. Basel: Karger, 1995: 101-108.
54. Furukawa Y, Shimadzu M, Rajput AH, et al. GTP-cyclohydrolase I gene mutations in hereditary progressive and dopa responsive dystonia. Ann Neurol 1996; 39: 609-617.
55. Furukawa Y, Nygaard TG, Gutlich M, et al. Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia. Neurology 1999; 53: 1032-1041.
56. Furukawa Y, Kapatos G, Haycock JW, et al. Brain biopterin and tyrosine hydroxylase in asymptomatic dopa-responsive dystonia. Ann Neurol 2002; 51: 637-641.
57. Nygaad TG, Wihelmsen KC, Risch NJ, et al. Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14q. Nat Genet 1993; 5: 386-391.
58. Nishiyama N, Yukishita S, Hagiwara S, et al. Gene mutation in hereditary progressive dystonia with marked diurnal fluctuation (HPD), strictly defined dopa-responsive dystonia. Brain Dev 2000; 22: 102-106.
59. Hirano M, Tamura Y, Nagai Y, et al. Exon skipping caused by a base substitution at a splice site in the GTP cyclohydrolase I gene in a Japanese family with hereditary progressive dystonia/dopa responsive dystonia. Biochem Biphys Res Commun 1995; 213: 645-646.
60. Hirano M, Tamaru Y, Ito H, et al. Mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive dystonia onset. Ann Neurol 1996; 40: 796-798.
61. Nygaad TG, Waran SP, Levine RA, et al. Dopa-responsive dystonia stimulating cerebral palsy. Pediatr Neurol 1994; 44: 236-240.
62. Furukawa Y, Kish SJ. Dopa-responsive dystonia: recent advances and remaining issues to be addressed. Mov Disord 1999; 14: 709-715.
63. Ichinose H, Ohye T, Segawa M, et al. GTP chclohydrolase I gene in hereditary progressive dystonia with marked diurnal fluctuation. Neurosci Lett 1995; 196: 5-8.
64. Furukawa Y, Guttman M, Sparagana SP, et al. Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene. Ann Neurol 2000; 47: 517-520.
65. Hirano M, Yanagihara T, Ueno S. Dominant negative effect of GTP cyclohydrolase I mutations in dopa-responsive hereditary progressive dystonia. Ann Neurol 1998; 44: 365-371.
66. Hwu WL, Chiou YW, Lai SY, et al. Dopa-responsive dystonia is induced by a dominantnegative mechanism. Ann Neurol 2000; 48: 609-613.
67. Suzuki T, Ohye T, Inagaki H, et al. Characterization of wild-type and mutants of recombinant human GTP cyclohydrolase I: relationship to etiology of dopa-responsive dystonia. J Neurochem 1999; 73: 2510-2516.
68. Ueno S, Hirano M. Missense mutants inactivate guanosine triphosphate cyclohydrolase I in hereditary progressive dystonia. Brain Dev 2000; 22(Suppl 1): S111-S114.
69. Shimoji M, Hirayama K, Hyland K, et al. GTP cyclohydrolase I gene expression in the brains of male and female hph-1 mice. J Neurochem 1999; 72: 757-764.
70. Davis MD, Ribeiro P, Tipper J, et al. "7-tetrahydrobiopterin,” a naturally occurring analogue of tetrahydrobiopterin, is a cofactor for and a potential inhibitor of the aromatic amino acid hydroxylases. Proc Natl Acad Sci U S A 1992; 89: 10109-10113.
71. McGeer EG, McGeer PL. Some characteristics of brain tyrosine hydroxylase. In: Mandel J, ed. New Concepts in Neurotransmitter Regulation. New York, London: Plenum, 1973: 53-68.
72. Steinfels FF, Heym J, Strecker R, et al. Behavioral correlates of dopaminergic unit activity in freely moving cats. Brain Res 1983; 25: 217-228.
73. Hibiya M, Ichinose H, Ozaki N, et al. Normal values and age-dependent changes in GTP cyclohydrolase I activity in stimulated mononuclear blood cells measured by highperformance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000; 740: 35-42.
74. Furukawa Y, Kish SJ. Influence of development and aging on brain biopterin: implications for dopa-responsive dystonia onset. Neurology 1998; 51: 632-634.
75. Shintaku H. Early diagnosis of 6-pyruvoyltetrahydropterin synthase deficiency. Pteridines 1994; 5: 18-27.
76. Graybiel AM, Ragsdale CW Jr. Histochemically distinct compartments in the striatum of human, monkey and cat demonstrated by acetylthiocholinesterase staining. Proc Natl Acad Sci 1978; 75: 5723-5726.
77. Gibb WRG. Selective pathology, disease pathogenesis and function in the basal ganglia. In: Kimura J, Shibasaki H, eds. Recent Advances in Clinical Neurophysiology. Amsterdam: Elsevier, 1996: 1009-1015.
78. Segawa M. Development of the nigrostriatal dopamine neuron and the pathways in the basal ganglia. Brain Dev 2000; 22: 1-4.
79. Nair VD, Mishra RK. Ontogenic development of dopamine D4 receptor in rat brain. Brain Res Dev Brain Res 1995; 90: 180-183.
80. Kreiss DS, Anderson LA, Waters JR. Apomorphine and dopamine D receptor agonists increase the firing rates of subthalamic nucleus neurons. Neuroscience 1996; 72: 863-876.
81. Kreiss DS, Mastropietro CW, Rawji SS, et al. The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson’s disease. J Neurosci 1997; 17: 6807-6819.
82. Nomura Y, Ikeuchi T, Tsuji S, et al. Two phenotypes and anticipation observed in Japanese cases with early-onset torsion dystonia (DYT 1). Brain Dev 2000; 22: 92-101.
83. Shima F, Sakata S, Sun SJ, et al. The role of the descending pallido-reticular pathway in movement disorders. In: Segawa M, Nomura Y, eds. Age-Related Dopamine-Dependent Disorders. Basel: Karger, 1995: 197-207.
84. Lenz FA, Seike MS, Jaeger CJ, et al. Single unit analysis of thalamus in patients with dystonia. Mov Disord 1992; 7(Suppl 1): 126.
85. Segawa M. Progress in Segawa’s disease. In: Mizuno Y, Fisher A, Hanin I, eds. Mapping the Progress of Alzheimer’s Disease and Parkinson’s Disease. New York: Kluwer Academic/Plenum, 2002: 353-359.
86. Segawa M. Discussant -pathophysiologies of Rett syndrome. Brain Dev 2001; 23(Suppl 1): S218-S223.
87. Leff SE, Rendahl KG, Spratt SK, et al. In vivo LEVODOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase. Exp Neurol 1998; 151: 249-264.
88. Sumi-Ichinose C, Urano F, Kuroda R, et al. Catecholamines and serotonin are differently regulated by tetrahydrobiopteri. A study from 6-pyruvoyltetrahydropterin synthase knockout mice. J Biol Chem 2001; 276: 41150-41160.
89. Furukawa Y, Lang AE, Trugman JM, et al. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology 1998; 50: 1015-1020.
90. Reisert I, Pilgrim C. Sexual differentiation of monoaminergic neuron genetic epigenetic. Trends Neurosci 1991; 14: 468-473.
91. Nomura Y, Uetake K, Yukishita S, et al. Dystonias responding to levodopa and failure in biopterin metabolism. Adv Neurol 1998; 78: 253-266.
92. Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 2000; 22(Suppl 1): S65-S80.
93. Blau N, Barnes I, Dhondt JL. International database of tetrahydrobiopterin deficiencies. J Inherit Metab Dis 1996; 19: 8-14.
94. Niederwieser A, Blau N, Wang M, et al. GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. Eur J Pediatr 1984; 141: 208-214.
95. Dudesek A, Roschinger W, Muntau AC, et al. Molecular analysis and long-term followup of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency. Eur J Pediatr 2001; 160: 267-276.
96. Liu TT, Chang YH, Chiang SH, et al. Identification of three novel 6-pyruvoyl-tetrahydropterin synthase gene mutations (226C>T, IVS3+1G>A, 116-119delTGTT) in Chinese hyperphenylalaninemia caused by tetrahydrobiopterin synthesis deficiency. Hum Mutat 2001; 18: 83.
97. Roze E, Vidailhet M, Blau N, et al. Long-term follow-up and adult outcome of 6-pyruvoyl- tetrahydropterin synthase deficiency. Mov Disord 2006; 21: 263-266.
98. Hanihara T, Inoue K, Kawanishi C, et al. 6-Pyruvoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study. Mov Disord 1997; 12: 408-411.
99. Demos MK, Waters PJ, Vallance HD, et al. 6-pyruvoyl-tetrahydropterin synthase deficiency with mild hyperphenylalaninemia. Ann Neurol 2005; 58: 164-167.
100. Tanaka Y, Matsuo N, Tsuzaki S, et al. On-off phenomenon in a child with tetrahydrobiopterin deficiency due to 6-pyruvoyl tetrahydropterin synthase deficiency (BH4 deficiency). Eur J Pediatr 1989; 148: 450-452.
101. Chien YH, Chiang SC, Huang A, et al. Treatment and outcome of Taiwanese patients with 6-pyruvoyltetrahydropterin synthase gene mutations. J Inherit Metab Dis 2001; 24: 815-823.
102. Thony B, Blau N. Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase genes. Hum Mutat 1997; 10: 11-20.
103. Oppliger T, Thony B, Kluge C, et al. Identification of mutations causing 6-pyruvoyltetrahydropterin synthase deficiency in four Italian families. Hum Mutat 1997; 10: 25-35.
104. Scherer-Oppliger T, Matasovic A, Laufs S, et al. Dominant negative allele (N47D) in a compound heterozygote for a variant of 6-pyruvoyltetrahydropterin synthase deficiency causing transient hyperphenylalaninemia. Hum Mutat 1999; 13: 286-289.
105. Bonafe L, Thony B, Penzien JM, et al. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 2001; 69: 269-277.
106. Neville BG, Parascandalo R, Farrugia R, et al. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 2005; 128: 2291-2296.
107. Blau N, Bonafe L, Thony B. Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of dopa-responsive dystonia and sepiapterin reductase deficiency. Mol Genet Metab 2001; 74: 172-185.
108. Cotton RG, Jennings I, Bracco G, et al. Tetrahydrobiopterin non-responsiveness in dihydropteridine reductase deficiency is associated with the presence of mutant protein. J Inherit Metab Dis 1986; 9: 239-243.
109. Castaigne P, Rondot P, Ribadeau-Dumas JL, et al. Progressive extra-pyramidal disorder in 2 young brothers. Remarkable effects of treatment with Levodopa (French). Rev Neurol (Paris) 1971; 124: 162-166.
110. Rondot P, Ziegler M. Dystonia-Levodopa responsive or juvenile parkinsonism? J Neural Transm Suppl 1983; 19: 273-281.
111. Knappskog PM, Flatmark T, Mallet J, et al. Recessively inherited LEVODOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 1995; 4: 1209-1212.
112. Hoffmann GF, Assmann B, Brautigam C, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol 2003; 54(Suppl 6): S56-S65.
113. Rondot P, Aicardi J, Goutieres F, et al. Dopa-sensitive dystonia (French). Rev Neurol (Paris) 1992; 148: 680-686.
114. Grattan-Smith PJ, Wevers RA, Steenbergen-Spanjers GC, et al. Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy. Mov Disord 2002; 17: 354-359.
115. Brautigam C, Steenbergen-Spanjers GC, Hoffmann GF, et al. Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. Clin Chem 1999; 45: 2073-2078.
116. Brautigam C, Wevers RA, Jansen RJ, et al. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 1998; 44: 1897-1904.
117. Wevers RA, de Rijk-van Andel JF, Brautigam C, et al. A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC). J Inherit Metab Dis 1999; 22: 364-373.
118. Dionisi-Vici C, Hoffmann GF, Leuzzi V, et al. Tyrosine hydroxylase deficiency with severe clinical course: clinical and biochemical investigations and optimization of therapy. J Pediatr 2000; 136: 560-562.
119. Ludecke B, Knappskog PM, Clayton PT, et al. Recessively inherited LEVODOPAresponsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996; 5: 1023-1028.
120. Swaans RJ, Rondot P, Renier WO, et al. Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism. Ann Hum Genet 2000; 64: 25-31.
121. Furukawa Y, Graf WD, Wong H, et al. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase gene mutations. Neurology 2001; 56: 260-263.
122. Janssen RJ, Wevers RA, Haussler M, et al. A branch site mutation leading to aberrant splicing of the human tyrosine hydroxylase gene in a child with a severe extrapyramidal movement disorder. Ann Hum Genet 2000; 64: 375-382.
123. Mason ST. Noradrenaline and behaviour. Trends Neurosci 1979; 2: 82-84.
124. Tanaka S, Miyagawa F, Imai H, et al. Learning abilities of the rats with lesion in the dorsal noradrenergic bundele (Japanese). Juntendo Med J (Tokyo) 1987; 33: 271-272.
125. Valzelli L, Garattini S. Biochemical and behavioural changes induced by isolation in rats. Neuropharmacology 1972; 11: 17-22.
126. Brenner E, Mirmiran M, Uylings HB, et al. Impaired growth of the cerebral cortex of rats treated neonatally with 6-hydroxydopamine under different environmental conditions. Neurosci Lett 1983; 42: 13-17.
127. Segawa M, Nomura Y. Pathophysiology of Austism: Evaluation of Sleep and locomotion. In: Tuchman R, Rapin I, eds. Autism: a neurological disorder of early brain development. International Review of Child Neurology Series (ICNA). London: Mac Keith Press, 2006: 248-264.
128. Mori S, Matsuyama K, Kohyama J, et al. Neuronal constituents of postural and locomotor control systems and their interactions in cats. Brain Dev 1992; 14(Suppl): S109-S120.
129. Grötzsch H, Pizzolato GP, Ghika J, et al. Neuropathology of a case of dopa-responsive dystonia associated with a new genetic locus, DYT14. Neurology 2002; 58(12): 1839-1842.
130. Yamamura Y, Sobue I, Ando K, et al. Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology 1973; 23: 239-244.
131. Yamamura Y, Hamaguchi Y, Uchida M, et al. Parkinsonism of early-onset with diurnal fluctuation. In: Segawa M, ed. Hereditary Progressive Dystonia with Marked Diurnal Fluctation. Carnforth: Parthenon, 1993: 51-59.
132. Matsumine M, Saito M, Shimoda-Matsubayashi S, et al. Localization of a gene for an autosomal recessive from of juvenile parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997; 60: 588-596.
133. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
134. Yokochi M. Clinicopathological identification of juvenile parkinsonism in reference to dopa-responsive disorders. In: Segawa M, ed. Hereditary Progressive Dystonia with Marked Diurnal Fluctuation. Carnforth: Parthenon, 1993: 37-47.
135. Kondo T, Mori H, Sugita Y, et al. Juvenile parkinsonian-a clinical, neuropathologic and biochemical study. Mov Disord 1997; 12 (Suppl 1): 32.
136. Sunohara N, Mano Y, Ando K, et al. Idiopathic dystonia: parkinsonism with marked diurnal fluctuation of symptoms. Ann Neurol 1985; 17: 39-45.
137. Sunohara N, Ikeda K, Tomi H. Idiopathic dystonia-parkinsonism with diurnal fluctuation: a follow-up study and magnetic resonance imaging findings. In: Segawa M, ed. Hereditary Progressive Dystonia with Marked Diurnal Fluctation. Carnforth: Parthenon, 1993: 61-70.
138. Yokochi M. Juvenile Parkinsons disease-part I. Clinical aspects (Japanese). Adv Neurol Sci (Tokyo) 1979; 23: 1060-1073.
139. Tassin J, Durr A, Bonnet A-M, et al. Levodopa-responsive dystonia: GTP cyclohydrolase I or parkin mutations? Brain 2000; 123: 1112-1121.
140. Furukawa Y. Genetics and biochemistry of dopa-responsive dystonia: significance of striatal tyrosine hydroxylase protein loss. Adv Neurol 2003; 91: 401-410.